ArticleFrontiers in immunology2023
Alterations of the fecal and vaginal microbiomes in patients with systemic lupus erythematosus and their associations with immunological profiles.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Coordinated oral-gut microbiota relocation in connective tissue diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- A cross-sectional analysis of the vaginal microenvironment in rheumatoid arthritis.Microbiology spectrum · 2026Article
- Distinct vaginal microbial signatures in pregnancies complicated by antiphospholipid syndrome: depletion ofMicrobiology spectrum · 2026Article
- The microbiota-systemic lupus erythematosus axis: mechanisms, diagnostics, and therapeutic frontiers.Frontiers in immunology · 2026Review
- Gut microbiota and metabolism in systemic lupus erythematosus: from dysbiosis to targeted interventions.European journal of medical research · 2025Review
- Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus.Biomarker research · 2025Article
- Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.The Journal of pharmacology and experimental therapeutics · 2025Review
- Association of Gut Dysbiosis with Disease Phenotype and Treatment in Systemic Lupus Erythematosus.Medical sciences (Basel, Switzerland) · 2025Article
- The Impact of Menopause on Autoimmune and Rheumatic Diseases.Clinical reviews in allergy & immunology · 2025Review
- Dysregulated Intestinal Host-Microbe Interactions in Systemic Lupus Erythematosus: Insights from Patients and Mouse Models.Microorganisms · 2025Review
- Gut microbiota dysbiosis and associated immune response in systemic lupus erythematosus: impact of disease and treatment.Gut pathogens · 2025Article
- Gut microbiota dysbiosis and systemic inflammation in elderly Chinese hypertensive patients: a case-control study.Frontiers in immunology · 2025Article
- Alteration in gut microbiota accompanied by increased intestinal permeability and Tfh/Tfr imbalance in patients with active SLE.Frontiers in cellular and infection microbiology · 2025Article
- Disclosing α-lactalbumin impact on the intestinal and vaginal microbiota of women suffering from polycystic ovary syndrome.Microbial biotechnology · 2024Article
- Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024Article
- Racial Differences in Plasma Microbial Translocation and Plasma Microbiome, Implications in Systemic Lupus Erythematosus Disease Pathogenesis.ACR open rheumatology · 2024Article
- Urinary microbiome profiling as a non-invasive tool for identifying biomarkers in systemic lupus erythematosus and lupus nephritis.Frontiers in cellular and infection microbiology · 2024Article
- The Disease with a Thousand Faces and the Human Microbiome-A Physiopathogenic Intercorrelation in Pediatric Practice.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Exploring the human microbiome in multiple body niches is beneficial for clinicians to determine which microbial dysbiosis should be targeted first. We aimed to study whether both the fecal and vaginal microbiomes are disrupted in SLE patients and whether they are correlated, as well as their associations with immunological features. Methods: A group of 30 SLE patients and 30 BMI-age-matched healthy controls were recruited. Fecal and vaginal samples were collected, the 16S rRNA gene was sequenced to profile microbiomes, and immunological features were examined. Results: Distinct fecal and vaginal bacterial communities and decreased microbial diversity in feces compared with the vagina were found in SLE patients and controls. Altered bacterial communities were found in the feces and vaginas of patients. Compared with the controls, the SLE group had slightly lower gut bacterial diversity, which was accompanied by significantly higher bacterial diversity in their vaginas. The most predominant bacteria differed between feces and the vagina in all groups. Eleven genera differed in patients' feces; for example, Conclusions: Although SLE patients had fecal and vaginal dysbiosis, dysbiosis in the vagina was more obvious than that in feces. Additionally, only the vaginal microbiome interacted with patients' immunological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.